Testimonials From Pharma-Biotech Product & Company Valuation

A very valuable course which covered the different aspects to consider, as well as the most common valuation models used. The course brought both an excellent overview of the subject, as well as touched upon quite specific details in a way that was easy to follow. I particularly enjoyed learning from the experiences in the group and Patrik's very pedagogical presentation of a complex topic. I would highly recommend the course.

Gedea Biotech

Annette Säfholm, CEO - Sweden - March 2023 (live online course)
Patrik is an experienced and conscientious trainer, ensuring that everyone is following but still sticking to time. The case studies were particularly helpful and I leave feeling "tooled-up" for future real-world application.


Marion Cubitt, Director, Discovery - United Kingdom - March 2023 (live online course)
I highly recommend this course to folks interested in learning about valuation basics. Patrik did a great job at walking us through the basics of each topic but also addressing the more advanced questions in a way that beginners in valuation can also grasp. It was nice to get to know the other colleagues in biotech who attended the course and learn from each other’s experiences. Thank you Patrik. Thank you also to CELforPharma for their support. I really appreciate all the hard work put in for the impeccable communication and coordination before and during the course.


Mohad Mehrabian, Technology & Venture Development - Canada - December 2022 (live online course)
Great course! It really perfected my knowledge in valuation. Many thanks to Patrik and CELforPharma for organising.


Dirk Groenewegen, Managing Director - The Netherlands - December 2022 (live online course)
Super organisation and a friendly and experienced trainer made for a very valuable and enjoyable course. I finally have a plan on how to approach valuations. Thanks!

Universität für Bodenkultur Wien

Lisa-Ariadne Schmidt, Technology Transfer Manager - Austria - December 2022 (live online course)
The course materials were good, the content was excellent, the mentoring approach was good, and working with other people was great. I learned a lot about methods of assessing the valuation of Biotech companies. Very useful.


Stéphane Woerly, President/Director Scientific - France - December 2022 (live online course)
I highly recommend CELforPharma online trainings as a fully professional place to improve your skills and industry knowledge.


Andrij Włach, Proxy & CFO - Poland - September 2022 (live online course)
An excellent course for the foundation of valuation needed especially for those involved in due diligence activities from both the investor and investee side of the business.

CSL Behring

Joe Salazar, Global Senior Director Plasma Product Development CMC Lead - Switzerland - September 2022 (live online course)
High quality and concise information. Excellent delivery and well-balanced in-course work to capture the nuances.

Edinburgh Innovations

Lysimachos Zografos, Entrepreneur-in-Residence, Wellcome Programme Lead - United Kingdom - September 2022 (live online course)
The group had very interesting discussions and the basic parts of the valuation puzzle were clearly communicated!

Bay Pharma

Nilesh Vaghela, Managing Director - Germany - September 2022 (live online course)
A brilliant session to work through the key considerations of valuation and the importance of this.

Oxford University Innovation

Susan Campbell, Licensing and Ventures Manager - United Kingdom - September 2022 (live online course)
This course was excellent and well worth the 3:30 AM start time!

Sunovion Pharmaceuticals

Jason Newcom, Director, Business Development and Alliance Management - United States - November 2021 (live online course)
A useful course, both for beginners and more experienced people.

Fondazione Telethon

Annamaria Merico, Head of Business Development - Italy - November 2021 (live online course)
This is the 3rd course from CELforPharma I attended, and the impression is positive again. I can recommend their BD courses for both BD and non-BD functions, either for specific needs or just as a general introduction.

Binnopharm Group

Svetlana Bolsheva, Strategy & Business Development Director - Russian Federation - November 2021 (live online course)
This course was a great use of my time. Very informative from theory to practice!

Sunovion Pharmaceuticals

Michael Segal, Executive Director, Business Development and Alliance Management - United States - November 2021 (live online course)
This was a valuable course taught by an experienced professional. The course met my expectations in terms of acquiring concrete knowledge for business application.

AC BioScience

Christine Evans, Legal and Compliance - Spain - May 2021 (live online course)
Very effective, high impact and high engagement course with very professional coordination and presentation!

Jamjoom Pharma

Horia Vilcu, Business Development Director - Saudi Arabia - May 2021 (live online course)
This great course delivered professionalism, valid expertise, knowledge and tools ready to implement! Looking forward to part II and other courses.


Nicole Fehrenbacher, Senior Innovation Scout - Belgium/Germany - May 2021 (live online course)
Very valuable to get some good insights in the challenges and mechanisms for valuation of pharma companies - highly recommended.

Let 'em know

Ola Bjorkman, CEO - Sweden - May 2021 (live online course)
The course provides valuation essentials and is a good first step into this topic. Everything was detailed enough to be beneficial, also if you already have some basic knowledge on this topic that you want to improve/reflect on. We got a useful overview regarding product/company valuation from Patrik, who presented the course with a high level of expertise and with excellent presentation skills.

Origimm Biotechnology

Florian Köck, Head of Finance & Business Operations - Austria - March 2021 (live online course)
This course was very comprehensive and Patrik Frei made some of the more complex notions very understandable, even for beginners in the field. I really enjoyed the case studies that allowed to apply the newly acquired notions in a practical way and helped a lot with understanding the more abstract ones. I came out with a better understanding and with practical tools that I can apply immediately in my every day work.


Hames Mainka, Manager Business Development - Germany - March 2021 (live online course)
Very clear course set-up and content that covered the full scope of Product & Company valuation at the right level of detail. I really appreciated the valuable case studies as breakout exercises. The group interaction worked very well with Zoom and the day was well managed by the CELforPharma team. Thanks a lot!

GATT Technologies

Jasper Groenenboom, Director Strategy & Finance - The Netherlands - March 2021 (live online course)
I thought it was a well-designed course that met the requirements for my role and anyone working in a Business Development department. My most valuable take-aways from the day were the topics on company valuation, the assessment of risk strategy and the interesting case studies we worked on during the breakout group work sessions. The expert was highly skilled in presenting and showed a high level of expertise on each topic. There was also great communication and follow-up with CELforPharma before, during and after the course which added to an excellent online course experience.

Paladin Labs

Martin Noel, Manager Business Development - Canada - March 2021 (live online course)
A very clear course that can be appreciated whether you have a financial background or not.

AMC Biotech

Ariane Mansouri, Consultant - Germany - March 2021 (live online course)
Good overview of valuation methods, for both a biotech company or a product. Thanks!


Guillaume Wégria, CEO - Belgium - March 2021 (live online course)
Thank you for setting up this virtual course and having been very responsive in all the preparation. Patrik did a great job keeping the audience engaged in an online format. He has a lot of expertise and experience, taking the audience gradually to the more complex aspects of valuation.


Clotilde de Vaux, Pipeline Strategy Manager - France - December 2020 (live online course)
Very comprehensive for all levels of knowledge. It refreshes knowledge about company valuation techniques with best practice examples. I also highly valued the example spreadsheets that were made available with the training materials. Patrik has a very calm and structured way of presenting, and answers all questions. The online format does not limit the learning experience at all. Thanks for a well-structured learning experience.


Franziska Finke, CFO - Germany - December 2020 (live online course)
Very useful course to outline the basics for valuations. Dr. Frei has great knowledge and the ability to explain in simple language so beginners can understand. Very good interaction with the other participants, even in this online format. Everyone appeared to engage well.


Gideon Gold, Financial Controller - United Kingdom - December 2020 (live online course)
Extensive overview of the most important topics to know in Pharma Business Development. Excellent speaker and reliable professional. Highly recommended!


Lucrezia Borgia, Corporate Licensing Associate, BD&L - Italy - December 2020 (live online course)
I really enjoyed this very well-structured and informative course. Patrik is a top expert in his field and was eager to share his knowledge. Highly valuable and recommended!

HealthTech Advisory

Marie-Helene Leopold, CEO - France - December 2020 (live online course)
Dr. Frei's course provides great insights and tools to anyone valuating life science projects!

Brand Institute

Alex Apelbaum, President - Switzerland - September 2020 (face-to-face course)
The course filled completely my expectations, in a small group and with a well prepared trainer, Patrik Frei. It gives a clear theoretical approach but also a practical case study to analyse and evaluate.


Davide D'Amico, CEO - Spain - September 2020 (face-to-face course)
Thanks for a great opportunity to engage in practical business valuation of pharma and biotech companies. It was very helpful and informative.

Faculty of Economic Sciences University of Warsaw

Anna Białek-Jaworska, Researcher / Assistant Professor - Poland - December 2019 (face-to-face course)
Great opportunity to take time out to consolidate learning and reflect on important elements of what drives valuation.

Cello Health

Jon Bircher, Chief Commercial Officer - United Kingdom - December 2019 (face-to-face course)
Excellent course, exceptionally clear advice in a complex field.

A'n'I Molecular

Hans Hoppe, CEO - United Kingdom - May 2019 (face-to-face course)
It's been a very good experience. Difficult concepts very easily explained. Highly recommendable.


Oriol Huguet, Head of Pipeline Development - Spain - May 2019 (face-to-face course)
The course structure, provided material and lecture content was excellent. Would definitely recommend it!


Tiziana Sonati, Director of Operations and Portfolio Manager - Switzerland - May 2019 (face-to-face course)
A highly relevant and clearly presented program with excellent materials. Recommended for all who are starting out in biotech deal-making.

Vicarius Pharma

Francis Marsland, General Counsel and Head of BD - Switzerland - November 2018 (face-to-face course)
Very knowledgeable, entertaining.


Remberto Martis, CEO - Germany - November 2018 (face-to-face course)
Good introductory-level course with interactive practice to apply the knowledge. I feel educated!

Amsterdam Neuroscience

Business Developer - The Netherlands - November 2018 (face-to-face course)
Very good course as introduction for assessing/valuing BioPharma Companies/Products.


Stephan Grosse, Controlling - Germany - November 2018 (face-to-face course)
This is a fantastic course - so interesting, informative & useful. The expert was most helpful and gave clear descriptions & examples.


Kieran Clarke, CEO - United Kingdom - October 2018 (face-to-face course)
Very insightful! Great breakdown of different perspectives of valuation!

Cura Innova Ventures

Kenneth Fernald, Partner - The Netherlands - March 2018 (face-to-face course)
Fantastic intro from a valuation veteran!

Eurofins BioPharma Product Testing

Marcel Langoor, Director Business Development - The Netherlands - March 2018 (face-to-face course)
Course was excellent. Patrik was very knowledgeable and I feel has given me a good platform to build upon creating my own valuation models.


Nick Cattle, Senior Analyst - United Kingdom - March 2018 (face-to-face course)
It’s a useful course to get an understanding of the frameworks being applied to valuating products, companies & deals.

Numab Therapeutics

Roland Helfenstein, Chief Financial Officer - Switzerland - November 2017 (face-to-face course)
This course gives very valuable valuation tools and understanding of value drivers and practitioner's knowledge of what assumptions are used in valuation. Moreover, it is very clear and understandable.

Vistula Bioventure

Anna Rzewuska, Managing Partner - Poland - November 2017 (face-to-face course)
Excellent content and relevant info. Great course overall!

Oxford Pharmascience

Chris Hill, Chief Financial Officer - United Kingdom - November 2017 (face-to-face course)
Very good in concept and presentation. The case studies are excellent!

Topadur Pharma

Markus Ducrey, Finance/Strategy - Switzerland - November 2017 (face-to-face course)
Very well-structured, easy-to-follow and thorough introduction to Valuation - as seen from different perspectives.


Ajla Hrle, BD Manager - Germany - March 2017 (face-to-face course)
Going in with some valuation experience, this course is great for considering different approaches to supplement your current valuation methods. Would highly recommend!


Saadia Basharat, Consultant - United Kingdom - March 2017 (face-to-face course)
Good validation of present day tools and structure in valuing products and companies.

Echelon-Frontier Scientific

Tim Miller, CEO and President - USA - March 2017 (face-to-face course)
A great course packed with useful tools in assessing and valuating biotech companies and products.

Medeon Science Park & Incubator

Ulf G Andersson, CEO - Sweden - March 2017 (face-to-face course)
Patrik’s course is a very good general introduction to company and product valuations in the field of life science, with great examples and material. I particularly liked the module on structuring a licensing deal. You can easily tell that Patrik has a vast experience in the field of valuation, both from the Academia and from the Industry, and I can really recommend this course. Thank you for a great learning experience!

Monocl Strategy Services

Jonathan Holmén, Associate - Sweden - October 2016 (face-to-face course)
This Valuation course is very useful and dynamic in terms of knowledge and skills. I particularly valued the step-by-step valuation process, the risk assessments in product valuation as well as the module on deal structuring and management. I highly recommend it!


Natalia Baldina, Manager - Russia - October 2016 (face-to-face course)
It is always a pleasure to meet real market professionals, with whom I can discuss and get valuable insight from. This course is of great help for my day-to-day work.


Alexander Nozdrachev, Business Development Director - Russia - April 2016 (face-to-face course)
Excellent overview of valuation of products & companies (in life sciences).

BioArctic Neuroscience

Gunilla Osswald, CEO - Sweden - April 2016 (face-to-face course)
As a CEO of a start-up that is currently raising money I found this valuation course just perfect!

Anaconda BioMed

Ofir Arad, CEO - Spain - April 2016 (face-to-face course)
Truly excellent course to learn the fundamentals of company and product valuations in biotech!


Priyaanka Nanduri, Consultant Analyst - United States - April 2016 (face-to-face course)
The valuation course led by Dr. Patrik Frei was an excellent introduction to both product and company valuation, which required no detailed prior knowledge of the topic. The course covered in detail the major valuation methods and their relative benefits and challenges, which was both informative and interesting. Perhaps the most useful elements of the course were the group practical exercises where we could put the theory we had learned into practice. I highly recommend this concise and expertly delivered course to any executives venturing into the murky, yet essential, world of asset and company valuation!

EUSA Pharma

Benjamin Owens, Business Development Director - United Kingdom - October 2015 (face-to-face course)
A valuable experience, and also useful for newcomers in the field of valuation


Daniele Colombo, Pipeline Development & Science Intelligence - Italy - October 2015 (face-to-face course)
Dr. Patrik Frei’s valuation course was first class. Patrik’s presentation style was natural and relaxed, with questions encouraged. The content was clear and easy to follow. The course notes and spreadsheet template provide permanent tools for business evaluation. Highly recommended!

Monitus Research

David Salisbury, Managing Director - United Kingdom - March 2015 (face-to-face course)
Very helpful for understanding the key elements, and nuances, of biotech company and product valuations.

Cellectar Biosciences

J. Patrick Genn, Vice President Business Development - United States of America - March 2015 (face-to-face course)
Definitely a great introduction course for inexperienced biotech people who are aiming to be part of a collaboration deal and want to become stronger in bargaining and to see what stands behind the proposed offer.


Jakub Jarolim, Strategy Analyst - Czech Republic - March 2015 (face-to-face course)
This course really met my expectations and covered important grey areas. The learned topics will allow me to interact with other functions in my company and during deals and negotiations.


Massimo Orlando, Head of International Marketing Intelligence - Italy - March 2015 (face-to-face course)
The course fitted perfectly with my needs for knowledge in this specific area!


Bas Sibeijn, General Manager - Germany - October 2014 (face-to-face course)
A complex subject but explained very well by Patrik. It was interesting to see all the elements used in valuation.

Sterling IP

Graham Golding, Valuation and Compliance Officer - UK - October 2014 (face-to-face course)
This course was a beautiful experience! Nice to share and talk with Pharma/Biotech professionals from different companies.

Caixa Capital Risc

Guillem Masferrer Bosch, Operations Analyst - Spain - October 2014 (face-to-face course)
Thank you very much for this course! Patrik Frei's Valuation course is perfect for preliminary understanding of biotech product and company valuation.

JSC Farmak

Kateryna Arnaut, Business Development Manager - Ukraine - October 2014 (face-to-face course)
Patrik Frei's Valuation course is very interesting and informative - Highly recommendable!

Wealth and Asset Management Solutions

Valdo Petrino, Portfolio Manager - Switzerland - October 2014 (face-to-face course)
Excellent summary of the principles of valuation. Great course overall!


Ahmed Mohamed, New Business Development Manager - UK - March 2014 (face-to-face course)
Patrik Frei demonstrated a lot of competence, even though the time was limited and the topic demanding.


Roland Meisel, Senior Director Business Development - Switzerland - March 2014 (face-to-face course)
Very practical course for someone who has little experience in the area.


Telma Faria Lapa Rodrigues Costa, Technical Director - Portugal - March 2014 (face-to-face course)
This course was recommended to me by my colleague and this was indeed perfect on all dimensions: expert, course content, organization and audience. I rated this course top level on all parameters - congratulations!


Scott Woodward, Head of BD - Norway - October 2013 (face-to-face course)
This course was to the point as an entry point to valuation methods. Perfect content.


Mikael Orum, CEO - Norway - March 2013 (face-to-face course)
Very impressive course which gives, in short time, deep insightful information about the topic.


Andreas von Planta, Owner - Switzerland - October 2012 (face-to-face course)
This was an excellent, very well-explained introductory course. I learned a lot! Good way of presenting complex info, congratulations!


Sascha Hugentobler, Swiss National Contact Point for FP7 Health - Switzerland - October 2012 (face-to-face course)
I enjoyed the workshop very much and appreciate the professional performance of the expert. This seminar helped me to understand better the valuation process.

Immune Pharma

Anna Baran, Director Corporate Development - USA - March 2012 (face-to-face course)
I found it very useful to participate and interact. I was already familiar with company valuation from the past, but seeing it in practice in a pharma-biotech setting, where the assumptions are so much more numerous and complex, was really an eye-opener. The material provided is also very helpful in my current role as a F&A Manager in Biotech.


Marc Moens, F&A Manager - Belgium - October 2011 (face-to-face course)
A very good course that explains the complex process of valuation in a way that is easy to understand.


Maria Fors, CEO - Sweden - October 2011 (face-to-face course)